We’re looking forward to attending the ASCO Annual Meeting, one of the most important global gatherings advancing innovation in oncology.

Prof. Dr. Matthias Schönermark, Chief Strategy Officer at Kintiga, will be representing the team alongside industry leaders, engaging in discussions on the evolving oncology landscape. Matthias is keen to engage on key topics that are strategically critical for our clients:

• How to generate evidence sufficient for European HTA authorities as populations become ever more narrowly stratified by biomarker
• How the growing complexity of combination therapies is straining comparator definitions in benefit assessment procedures, and
• How European market access will develop under shifting international pricing and Most Favoured Nation (MFN) frameworks

If you are attending ASCO and would like to connect, exchange perspectives, or discuss current challenges and opportunities in oncology and market access and the future of European market access amid evolving international pricing and MFN frameworks—please feel free to reach out to Matthias via email.